Articles for Business
October 31, 2016 | Laura Joszt
Various stakeholders in the healthcare industry are trying to determine value in healthcare, and speakers representing the pharmaceutical industry, research, and the patient perspective discussed the topic during the VBID Summit.
October 15, 2016 | Priyam Vora
Between 2005 and 2013, the United States prescription drug market grew at an average annual pace of 1.8%. The same market experienced a dramatic growth rate in 2014 of 11.5%.
October 13, 2016 |
Patricia Salber, MD, MBA, of The Doctor Weighs In, doesn’t believe the healthcare industry will become anything like that of the retail or travel industry, as healthcare is very complicated and consumers may not always be making their own decisions, especially in cases where patients are seeking hospital treatment.
October 12, 2016 | Laura Joszt
As the public grows increasingly outraged over the rising cost of prescription drugs, the cost of hospital inpatient drugs has been overlooked. According to a new report, inpatient drug spending increased 23.4% annually between 2013 and 2015.
October 12, 2016 |
Payment reform in the United States is moving quickly, but there are still a lot of unknowns among providers. Meetings like the ACO & Emerging Healthcare Delivery Coalition help accountable care organizations (ACOs) and providers share best practices and figure out how to succeed, said Mark McClellan, MD, PhD, director of the Duke-Margolis Center for Health Policy and keynote speaker at the ACO Coalition's fall meeting in Philadelphia, Pennsylvania, October 20-21. Learn more about the meeting and register.
October 10, 2016 | Mary Caffrey
A letter from CMS Acting Administrator Andy Slavitt that was made public said that Mylan had been warned repeatedly that it was not using the right classification for the EpiPen, at taxpayers' expense.
September 20, 2016 |
Ideally, the healthcare industry needs to be more consumer driven, so that solutions and programs are built with the patient in mind, said Jay Sheehy, senior vice president of product innovation at EmblemHealth.
September 19, 2016 | AJMC Staff
What we're reading, September 19, 2016: the government update rules on reporting clinical trial findings; hospitals say they aren't receiving discounts for Valeant's heart drugs; and the FDA approved the first treatment for Duchenne muscular dystrophy.